The Drug-Resistant Tuberculosis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Drug-Resistant Tuberculosis Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital Pharmacy accounting for % of the Drug-Resistant Tuberculosis Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While First-Line Anti-TB Drugs segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Drug-Resistant Tuberculosis Treatment include Sanofi, Novartis AG, Endo International plc, CMP Pharma, and STI Pharma LLC, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Drug-Resistant Tuberculosis Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
First-Line Anti-TB Drugs
Second-Line Anti-TB Drugs
Others
Market segment by Application, can be divided into
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Others
Market segment by players, this report covers
Sanofi
Novartis AG
Endo International plc
CMP Pharma
STI Pharma LLC
Akorn Incorporated
Lupin
Johnson & Johnson Services Inc.
Macleods Pharmaceuticals Ltd
Pfizer Inc
Hikma Pharmaceuticals PLC
Lannett
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Fresenius Kabi AG
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Drug-Resistant Tuberculosis Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Drug-Resistant Tuberculosis Treatment, with revenue, gross margin and global market share of Drug-Resistant Tuberculosis Treatment from 2019 to 2022.
Chapter 3, the Drug-Resistant Tuberculosis Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Drug-Resistant Tuberculosis Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Drug-Resistant Tuberculosis Treatment research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Drug-Resistant Tuberculosis Treatment
1.2 Classification of Drug-Resistant Tuberculosis Treatment by Type
1.2.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Type in 2021
1.2.3 First-Line Anti-TB Drugs
1.2.4 Second-Line Anti-TB Drugs
1.2.5 Others
1.3 Global Drug-Resistant Tuberculosis Treatment Market by Application
1.3.1 Overview: Global Drug-Resistant Tuberculosis Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacy
1.3.3 Online Pharmacy
1.3.4 Retail Pharmacy
1.3.5 Others
1.4 Global Drug-Resistant Tuberculosis Treatment Market Size & Forecast
1.5 Global Drug-Resistant Tuberculosis Treatment Market Size and Forecast by Region
1.5.1 Global Drug-Resistant Tuberculosis Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Drug-Resistant Tuberculosis Treatment Market Size by Region, (2017-2022)
1.5.3 North America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Drug-Resistant Tuberculosis Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Drug-Resistant Tuberculosis Treatment Market Drivers
1.6.2 Drug-Resistant Tuberculosis Treatment Market Restraints
1.6.3 Drug-Resistant Tuberculosis Treatment Trends Analysis
2 Company Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
2.1.4 Sanofi Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Sanofi Recent Developments and Future Plans
2.2 Novartis AG
2.2.1 Novartis AG Details
2.2.2 Novartis AG Major Business
2.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.2.4 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Novartis AG Recent Developments and Future Plans
2.3 Endo International plc
2.3.1 Endo International plc Details
2.3.2 Endo International plc Major Business
2.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.3.4 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Endo International plc Recent Developments and Future Plans
2.4 CMP Pharma
2.4.1 CMP Pharma Details
2.4.2 CMP Pharma Major Business
2.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
2.4.4 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 CMP Pharma Recent Developments and Future Plans
2.5 STI Pharma LLC
2.5.1 STI Pharma LLC Details
2.5.2 STI Pharma LLC Major Business
2.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.5.4 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 STI Pharma LLC Recent Developments and Future Plans
2.6 Akorn Incorporated
2.6.1 Akorn Incorporated Details
2.6.2 Akorn Incorporated Major Business
2.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
2.6.4 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Akorn Incorporated Recent Developments and Future Plans
2.7 Lupin
2.7.1 Lupin Details
2.7.2 Lupin Major Business
2.7.3 Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
2.7.4 Lupin Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Lupin Recent Developments and Future Plans
2.8 Johnson & Johnson Services Inc.
2.8.1 Johnson & Johnson Services Inc. Details
2.8.2 Johnson & Johnson Services Inc. Major Business
2.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.8.4 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Johnson & Johnson Services Inc. Recent Developments and Future Plans
2.9 Macleods Pharmaceuticals Ltd
2.9.1 Macleods Pharmaceuticals Ltd Details
2.9.2 Macleods Pharmaceuticals Ltd Major Business
2.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.9.4 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
2.10 Pfizer Inc
2.10.1 Pfizer Inc Details
2.10.2 Pfizer Inc Major Business
2.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
2.10.4 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Pfizer Inc Recent Developments and Future Plans
2.11 Hikma Pharmaceuticals PLC
2.11.1 Hikma Pharmaceuticals PLC Details
2.11.2 Hikma Pharmaceuticals PLC Major Business
2.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
2.11.4 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Hikma Pharmaceuticals PLC Recent Developments and Future Plans
2.12 Lannett
2.12.1 Lannett Details
2.12.2 Lannett Major Business
2.12.3 Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
2.12.4 Lannett Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Lannett Recent Developments and Future Plans
2.13 Mylan N.V.
2.13.1 Mylan N.V. Details
2.13.2 Mylan N.V. Major Business
2.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
2.13.4 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Mylan N.V. Recent Developments and Future Plans
2.14 Teva Pharmaceutical Industries Ltd
2.14.1 Teva Pharmaceutical Industries Ltd Details
2.14.2 Teva Pharmaceutical Industries Ltd Major Business
2.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
2.14.4 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
2.15 Fresenius Kabi AG
2.15.1 Fresenius Kabi AG Details
2.15.2 Fresenius Kabi AG Major Business
2.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
2.15.4 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Fresenius Kabi AG Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Drug-Resistant Tuberculosis Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Drug-Resistant Tuberculosis Treatment Players Market Share in 2021
3.2.2 Top 10 Drug-Resistant Tuberculosis Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Drug-Resistant Tuberculosis Treatment Players Head Office, Products and Services Provided
3.4 Drug-Resistant Tuberculosis Treatment Mergers & Acquisitions
3.5 Drug-Resistant Tuberculosis Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Drug-Resistant Tuberculosis Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Drug-Resistant Tuberculosis Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2028)
6.2 North America Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2028)
6.3 North America Drug-Resistant Tuberculosis Treatment Market Size by Country
6.3.1 North America Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2028)
6.3.2 United States Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2028)
7.2 Europe Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2028)
7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country
7.3.1 Europe Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2028)
7.3.2 Germany Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
7.3.3 France Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Drug-Resistant Tuberculosis Treatment Market Size by Region
8.3.1 Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Region (2017-2028)
8.3.2 China Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
8.3.5 India Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2028)
9.2 South America Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2028)
9.3 South America Drug-Resistant Tuberculosis Treatment Market Size by Country
9.3.1 South America Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Country
10.3.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Drug-Resistant Tuberculosis Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Drug-Resistant Tuberculosis Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Drug-Resistant Tuberculosis Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Drug-Resistant Tuberculosis Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Drug-Resistant Tuberculosis Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Region (2023-2028)
Table 6. Sanofi Corporate Information, Head Office, and Major Competitors
Table 7. Sanofi Major Business
Table 8. Sanofi Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 9. Sanofi Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 11. Novartis AG Major Business
Table 12. Novartis AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 13. Novartis AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Endo International plc Corporate Information, Head Office, and Major Competitors
Table 15. Endo International plc Major Business
Table 16. Endo International plc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 17. Endo International plc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. CMP Pharma Corporate Information, Head Office, and Major Competitors
Table 19. CMP Pharma Major Business
Table 20. CMP Pharma Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 21. CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. STI Pharma LLC Corporate Information, Head Office, and Major Competitors
Table 23. STI Pharma LLC Major Business
Table 24. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 25. STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Akorn Incorporated Corporate Information, Head Office, and Major Competitors
Table 27. Akorn Incorporated Major Business
Table 28. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 29. Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Lupin Corporate Information, Head Office, and Major Competitors
Table 31. Lupin Major Business
Table 32. Lupin Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 33. Lupin Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Johnson & Johnson Services Inc. Corporate Information, Head Office, and Major Competitors
Table 35. Johnson & Johnson Services Inc. Major Business
Table 36. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 37. Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Macleods Pharmaceuticals Ltd Corporate Information, Head Office, and Major Competitors
Table 39. Macleods Pharmaceuticals Ltd Major Business
Table 40. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 41. Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 43. Pfizer Inc Major Business
Table 44. Pfizer Inc Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 45. Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Hikma Pharmaceuticals PLC Corporate Information, Head Office, and Major Competitors
Table 47. Hikma Pharmaceuticals PLC Major Business
Table 48. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 49. Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Lannett Corporate Information, Head Office, and Major Competitors
Table 51. Lannett Major Business
Table 52. Lannett Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 53. Lannett Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Mylan N.V. Corporate Information, Head Office, and Major Competitors
Table 55. Mylan N.V. Major Business
Table 56. Mylan N.V. Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 57. Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Teva Pharmaceutical Industries Ltd Corporate Information, Head Office, and Major Competitors
Table 59. Teva Pharmaceutical Industries Ltd Major Business
Table 60. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 61. Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Fresenius Kabi AG Corporate Information, Head Office, and Major Competitors
Table 63. Fresenius Kabi AG Major Business
Table 64. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product and Solutions
Table 65. Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Global Drug-Resistant Tuberculosis Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 67. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 68. Breakdown of Drug-Resistant Tuberculosis Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 69. Drug-Resistant Tuberculosis Treatment Players Head Office, Products and Services Provided
Table 70. Drug-Resistant Tuberculosis Treatment Mergers & Acquisitions in the Past Five Years
Table 71. Drug-Resistant Tuberculosis Treatment New Entrants and Expansion Plans
Table 72. Global Drug-Resistant Tuberculosis Treatment Revenue (USD Million) by Type (2017-2022)
Table 73. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Type (2017-2022)
Table 74. Global Drug-Resistant Tuberculosis Treatment Revenue Forecast by Type (2023-2028)
Table 75. Global Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2022)
Table 76. Global Drug-Resistant Tuberculosis Treatment Revenue Forecast by Application (2023-2028)
Table 77. North America Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2022) & (USD Million)
Table 78. North America Drug-Resistant Tuberculosis Treatment Revenue by Type (2023-2028) & (USD Million)
Table 79. North America Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2022) & (USD Million)
Table 80. North America Drug-Resistant Tuberculosis Treatment Revenue by Application (2023-2028) & (USD Million)
Table 81. North America Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2022) & (USD Million)
Table 82. North America Drug-Resistant Tuberculosis Treatment Revenue by Country (2023-2028) & (USD Million)
Table 83. Europe Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2022) & (USD Million)
Table 84. Europe Drug-Resistant Tuberculosis Treatment Revenue by Type (2023-2028) & (USD Million)
Table 85. Europe Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2022) & (USD Million)
Table 86. Europe Drug-Resistant Tuberculosis Treatment Revenue by Application (2023-2028) & (USD Million)
Table 87. Europe Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2022) & (USD Million)
Table 88. Europe Drug-Resistant Tuberculosis Treatment Revenue by Country (2023-2028) & (USD Million)
Table 89. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2022) & (USD Million)
Table 90. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Type (2023-2028) & (USD Million)
Table 91. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2022) & (USD Million)
Table 92. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Application (2023-2028) & (USD Million)
Table 93. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Region (2017-2022) & (USD Million)
Table 94. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue by Region (2023-2028) & (USD Million)
Table 95. South America Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2022) & (USD Million)
Table 96. South America Drug-Resistant Tuberculosis Treatment Revenue by Type (2023-2028) & (USD Million)
Table 97. South America Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2022) & (USD Million)
Table 98. South America Drug-Resistant Tuberculosis Treatment Revenue by Application (2023-2028) & (USD Million)
Table 99. South America Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2022) & (USD Million)
Table 100. South America Drug-Resistant Tuberculosis Treatment Revenue by Country (2023-2028) & (USD Million)
Table 101. Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Type (2017-2022) & (USD Million)
Table 102. Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Type (2023-2028) & (USD Million)
Table 103. Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Application (2017-2022) & (USD Million)
Table 104. Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Application (2023-2028) & (USD Million)
Table 105. Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Country (2017-2022) & (USD Million)
Table 106. Middle East & Africa Drug-Resistant Tuberculosis Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Drug-Resistant Tuberculosis Treatment Picture
Figure 2. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Type in 2021
Figure 3. First-Line Anti-TB Drugs
Figure 4. Second-Line Anti-TB Drugs
Figure 5. Others
Figure 6. Drug-Resistant Tuberculosis Treatment Revenue Market Share by Application in 2021
Figure 7. Hospital Pharmacy Picture
Figure 8. Online Pharmacy Picture
Figure 9. Retail Pharmacy Picture
Figure 10. Others Picture
Figure 11. Global Drug-Resistant Tuberculosis Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Drug-Resistant Tuberculosis Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Region (2017-2028)
Figure 14. Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Region in 2021
Figure 15. North America Drug-Resistant Tuberculosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Drug-Resistant Tuberculosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Drug-Resistant Tuberculosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Drug-Resistant Tuberculosis Treatment Market Drivers
Figure 21. Drug-Resistant Tuberculosis Treatment Market Restraints
Figure 22. Drug-Resistant Tuberculosis Treatment Market Trends
Figure 23. Sanofi Recent Developments and Future Plans
Figure 24. Novartis AG Recent Developments and Future Plans
Figure 25. Endo International plc Recent Developments and Future Plans
Figure 26. CMP Pharma Recent Developments and Future Plans
Figure 27. STI Pharma LLC Recent Developments and Future Plans
Figure 28. Akorn Incorporated Recent Developments and Future Plans
Figure 29. Lupin Recent Developments and Future Plans
Figure 30. Johnson & Johnson Services Inc. Recent Developments and Future Plans
Figure 31. Macleods Pharmaceuticals Ltd Recent Developments and Future Plans
Figure 32. Pfizer Inc Recent Developments and Future Plans
Figure 33. Hikma Pharmaceuticals PLC Recent Developments and Future Plans
Figure 34. Lannett Recent Developments and Future Plans
Figure 35. Mylan N.V. Recent Developments and Future Plans
Figure 36. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
Figure 37. Fresenius Kabi AG Recent Developments and Future Plans
Figure 38. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Players in 2021
Figure 39. Drug-Resistant Tuberculosis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 40. Global Top 3 Players Drug-Resistant Tuberculosis Treatment Revenue Market Share in 2021
Figure 41. Global Top 10 Players Drug-Resistant Tuberculosis Treatment Revenue Market Share in 2021
Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 43. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Type in 2021
Figure 44. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Type (2023-2028)
Figure 45. Global Drug-Resistant Tuberculosis Treatment Revenue Share by Application in 2021
Figure 46. Global Drug-Resistant Tuberculosis Treatment Market Share Forecast by Application (2023-2028)
Figure 47. North America Drug-Resistant Tuberculosis Treatment Sales Market Share by Type (2017-2028)
Figure 48. North America Drug-Resistant Tuberculosis Treatment Sales Market Share by Application (2017-2028)
Figure 49. North America Drug-Resistant Tuberculosis Treatment Revenue Market Share by Country (2017-2028)
Figure 50. United States Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Canada Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Mexico Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Europe Drug-Resistant Tuberculosis Treatment Sales Market Share by Type (2017-2028)
Figure 54. Europe Drug-Resistant Tuberculosis Treatment Sales Market Share by Application (2017-2028)
Figure 55. Europe Drug-Resistant Tuberculosis Treatment Revenue Market Share by Country (2017-2028)
Figure 56. Germany Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. France Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. United Kingdom Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Russia Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Italy Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales Market Share by Type (2017-2028)
Figure 62. Asia-Pacific Drug-Resistant Tuberculosis Treatment Sales Market Share by Application (2017-2028)
Figure 63. Asia-Pacific Drug-Resistant Tuberculosis Treatment Revenue Market Share by Region (2017-2028)
Figure 64. China Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Japan Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South Korea Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. India Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Southeast Asia Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Australia Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. South America Drug-Resistant Tuberculosis Treatment Sales Market Share by Type (2017-2028)
Figure 71. South America Drug-Resistant Tuberculosis Treatment Sales Market Share by Application (2017-2028)
Figure 72. South America Drug-Resistant Tuberculosis Treatment Revenue Market Share by Country (2017-2028)
Figure 73. Brazil Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Argentina Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Middle East and Africa Drug-Resistant Tuberculosis Treatment Sales Market Share by Type (2017-2028)
Figure 76. Middle East and Africa Drug-Resistant Tuberculosis Treatment Sales Market Share by Application (2017-2028)
Figure 77. Middle East and Africa Drug-Resistant Tuberculosis Treatment Revenue Market Share by Country (2017-2028)
Figure 78. Turkey Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Saudi Arabia Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. UAE Drug-Resistant Tuberculosis Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Methodology
Figure 82. Research Process and Data Source
Publisher: GlobalInfoResearch
Related Reports
- Global Oncology Based Preclinical CRO Market Analysis and Forecast, 2022-2028
- Global Neurology Clinical Trials Market Analysis and Forecast, 2022-2028
- Global Disposable 3-ply Face Masks Market Analysis and Forecast, 2022-2028
- Global Diabetic Foot Ulcer Therapy Market Analysis and Forecast, 2022-2028
- India Biotechnology Market Analysis and Forecast, 2022-2028
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support